Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 26

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 26
---
 and more effective than competing products.

| 3 | https://www.ke.hku.hk/story/innovation/the-magic-of-chinese-yam-for-treatment-of-menopausal-syndrome; 
 see also, Scientific Reports, 5-10179.                                                                |

| 4 | https://www.everydayhealth.com/menopause/osteoporosis-and-menopause.aspx |

<div align='center'>S-14</div>

Inflation

Inflation affects us by generally
increasing our cost of labor and research and development costs, the way it does to all labor and research costs. However, we do not anticipate
that inflation will materially affect our business in the foreseeable future.

Seasonality

We believe our operation and sales do
not experience seasonality.

Employees

As of the date hereof, we have
we have 2 full-time employees, one of whom is the Chief Executive Officer and the other who is engaged in general and administrative functions
and who is located in Asia. We have also engaged and may continue to engage 5 independent contracted consultants and advisors to assist
us with our operations. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We have
never experienced any employment related work stoppages, and we consider our relations with our employees to be good.

Intellectual Property

The technologies underlying
our various research and development projects are the subject of various patents and patent applications claiming, in certain instances,
composition of matter and, in other instances, methods of use. Prosecution, maintenance, and enforcement of these patents, as well as
those on any future protectable technologies we may acquire, are and will continue to be an important part of our strategy to develop
and commercialize novel medicines, as described in more detail below. Through entering into license agreements with their owners, we have
obtained exclusive rights to these patents, applications and related know-how in the U.S. and certain other countries to develop,
manufacture and commercialize the products using or incorporating the protected inventions that are described in this proxy statement/prospectus
and that are expected to contribute significant value to our business. The technologies protected by these patents may also for the basis
for the development of other products.

In addition to licensed intellectual
property, our in-house science team has been actively developing our own proprietary intellectual property. Thus far, the only patents
or non-provisional patent applications that have been filed in the Company’s own name for the Lead